Denali Therapeutics Stock Performance
| DNLI Stock | USD 15.56 0.55 3.41% |
The firm shows a Beta (market volatility) of 3.42, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. Denali Therapeutics right now shows a risk of 6.13%. Please confirm Denali Therapeutics sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Denali Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong essential indicators, Denali Therapeutics is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return (3.17) | Five Day Return (5.45) | Year To Date Return (27.07) | Ten Year Return (27.27) | All Time Return (27.27) |
1 | Disposition of 1666 shares by Vicki Sato of Denali Therapeutics at 18.37 subject to Rule 16b-3 | 02/15/2024 |
2 | Denali stock slips as Sanofi fails in mid-stage ALS trial | 02/16/2024 |
3 | Denali Therapeutics Trading Down 9.2 percent After Earnings Miss | 02/28/2024 |
4 | Alps Advisors Inc. Raises Stock Position in Denali Therapeutics Inc. | 03/07/2024 |
5 | Disposition of 9972 shares by Carole Ho of Denali Therapeutics at 19.43 subject to Rule 16b-3 | 03/11/2024 |
6 | Denali Therapeutics NASDAQDNLI investor three-year losses grow to 67 percent as the stock sheds US223m this past week | 03/19/2024 |
7 | Disposition of 2784 shares by Carole Ho of Denali Therapeutics at 17.29 subject to Rule 16b-3 | 03/20/2024 |
8 | Denali Therapeutics Inc.s Price Is Right But Growth Is Lacking After Shares Rocket 25 | 03/21/2024 |
9 | Why Is Denali Therapeutics Up 2.8 percent Since Last Earnings Report | 03/28/2024 |
10 | Disposition of 92500 shares by Steve Krognes of Denali Therapeutics at 20.5 subject to Rule 16b-3 | 04/01/2024 |
11 | Why Denali Therapeutics Stock Might be a Great Pick | 04/09/2024 |
12 | An Intrinsic Calculation For Denali Therapeutics Inc. Suggests Its 44 percent Undervalued | 04/17/2024 |
| Begin Period Cash Flow | 218 M |
Denali |
Denali Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,687 in Denali Therapeutics on January 26, 2024 and sell it today you would lose (131.00) from holding Denali Therapeutics or give up 7.77% of portfolio value over 90 days. Denali Therapeutics is currently generating 0.0331% in daily expected returns and assumes 6.1268% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Denali, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Denali Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Denali Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Denali Therapeutics, and traders can use it to determine the average amount a Denali Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0054
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DNLI |
Estimated Market Risk
| 6.13 actual daily | 54 54% of assets are less volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Denali Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Denali Therapeutics by adding Denali Therapeutics to a well-diversified portfolio.
Denali Therapeutics Fundamentals Growth
Denali Stock prices reflect investors' perceptions of the future prospects and financial health of Denali Therapeutics, and Denali Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Denali Stock performance.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0941 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 1.24 B | ||||
| Shares Outstanding | 142.54 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 7.69 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (250.27 M) | ||||
| EBITDA | (179.97 M) | ||||
| Net Income | (145.22 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 52.24 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 7.45 X | ||||
| Cash Flow From Operations | (357.99 M) | ||||
| Earnings Per Share | (1.06) X | ||||
| Market Capitalization | 2.3 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 986.15 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
About Denali Therapeutics Performance
To evaluate Denali Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Denali Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Denali Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Denali Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Denali's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.000022 | 0.000023 | |
| Return On Tangible Assets | (0.13) | (0.13) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about Denali Therapeutics performance evaluation
Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Denali Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: An Intrinsic Calculation For Denali Therapeutics Inc. Suggests Its 44 percent Undervalued |
- Analyzing Denali Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Denali Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Denali Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Denali Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Denali Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Denali Therapeutics' stock. These opinions can provide insight into Denali Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.06) | Revenue Per Share 2.406 | Quarterly Revenue Growth (1.00) | Return On Assets (0.09) | Return On Equity (0.14) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.